Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on March 26, 2018. The report discloses corporate governance changes effective March 22, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $37,500 for the new director.
- Stock Option Grant: 36,800 shares with an exercise price of $10.50 per share.
Material Changes
The primary material change is the appointment of Ivana Magovcevic-Liebisch as a Class II director and member of the Audit Committee. This appointment includes a standard indemnification agreement and the grant of equity compensation vesting monthly over three years.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No risks or contingencies are disclosed in this specific report, other than the standard disclosure that the director has no material interest in transactions requiring Item 404(a) disclosure.
Investor Verification Checklist
- Verify the correct registrant name is Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Confirm the vesting schedule and exercise price ($10.50) of the 36,800 stock options granted to Dr. Magovcevic-Liebisch.
- Review the Company's existing compensation policy for non-employee directors to validate the $37,500 retainer.
- Check the Form S-1 filed on September 14, 2015, for the referenced standard indemnification agreement (Exhibit 10.1).